TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Drug: Tulmimetostat
Sites in Iowa City +7 more locations
Sponsor: Novartis Pharmaceuticals
Sex: Male·Age: 18+
Code: NCT07190300·Phase 1, Phase 2·Recruiting·Listed Sep 2025